Background: A genetic association/prospective follow-up study was conducted to investigate whether genetic variation of the alpha(2B)-adrenergic receptor gene was associated with the risk of restenosis in 96 Greek coronary artery disease patients undergoing coronary angioplasty and stent implantation.
Methods: For comparison of genotype frequency, a control group of 83 asymptomatic individuals was also studied. The end-point of the current study was the incidence of restenosis at 7 months of clinical follow-up.
Results: The majority of patients (70/96) had the insertion/insertion genotype, fewer patients (23/96) had the insertion/deletion genotype and only 3/96 had the deletion/deletion genotype; overall the frequency distribution was not different from that of the control subjects. Restenosis occurred in 15 of the 96 patients.
Conclusions: In the population studied, alpha(2B)-adrenoreceptor polymorphisms were not found to predispose patients to an increased incidence of restenosis. Nevertheless, these findings should be considered as preliminary, taking into account the small number of patients that were studied and the rarity of the deletion/deletion genotype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1515/CCLM.2006.155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Centhaquine Increases Stroke Volume and Cardiac Output in Patients with Hypovolemic Shock.
J Clin Med
June 2024
Pharmazz Inc., Research and Development, Willowbrook, IL 60527, USA.
Centhaquine is a resuscitative agent that acts on α2B adrenergic receptors. Its effect on cardiac output in hypovolemic shock patients has not been reported. This pilot study was conducted in 12 hypovolemic shock patients treated with centhaquine who participated in an open-label phase IV study (NCT05956418).
View Article and Find Full Text PDFSustained Alleviation of Autoimmunity by Activating α2B-adrenergic Receptors.
J Immunol
August 2024
Alceptor Therapeutics, Newport Beach, CA.
Article Synopsis
- Catecholamines interact with α- and β-adrenergic receptors on immune cells, influencing immune responses, particularly through α2-adrenergic receptors.
- The study identifies AGN-762 as a selective agonist for the α2B and α2C subtypes, reducing disease symptoms in an experimental model of autoimmune disease by affecting T regulatory cells.
- Importantly, AGN-762 does not cause the sedative or cardiovascular side effects typical of other α2A subtype agonists, suggesting its potential as a new treatment strategy for autoimmune conditions.
Evolutionary Unmasking Resuscitative Therapeutics Potential of Centhaquin Citrate in Hypovolemic Shock.
CNS Neurol Disord Drug Targets
June 2024
Chitkara College of Pharmacy, Chitkara University, Punjab, India.
Hypovolemic shock (HS), a clinical condition of insufficient blood perfusion and oxygenation in body tissues, is associated with immense morbidity and mortality. Treatment approaches include fluid replacement and surgical repair of reversible causes of hemorrhage; however, they cause irreversible blood perfusion loss, systemic inflammation, multiple organ failure, and death. Centhaquin citrate (CC) is an innovative centrally acting cardiovascular active agent that is initially intended as an antihypertensive drug.
View Article and Find Full Text PDFGTPγS Assay for Measuring Agonist-Induced Desensitization of Two Human Polymorphic Alpha-Adrenoceptor Variants.
Methods Mol Biol
September 2022
Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, FL, USA.
α-Adrenergic receptors (ARs) mediate many cellular actions of epinephrine and norepinephrine, including inhibition of their secretion (sympathetic inhibition) from adrenal chromaffin cells. Like many other G protein-coupled receptors (GPCRs), they undergo agonist-dependent phosphorylation and desensitization by GPCR kinases (GRKs), a phenomenon recently shown to play a major role in the sympathetic overdrive that accompanies and aggravates chronic heart failure. A three-glutamic acid deletion polymorphism in the human α-AR subtype gene (Glu301-303) causes impaired agonist-promoted receptor phosphorylation and desensitization, resulting in enhanced signaling to inhibition of cholinergic-induced catecholamine secretion in adrenal chromaffin cells.
View Article and Find Full Text PDFYohimbine, an α2-Adrenoceptor Antagonist, Suppresses PDGF-BB-Stimulated Vascular Smooth Muscle Cell Proliferation by Downregulating the PLCγ1 Signaling Pathway.
Int J Mol Sci
July 2022
Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 110, Taiwan.
Yohimbine (YOH) has antiproliferative effects against breast cancer and pancreatic cancer; however, its effects on vascular proliferative diseases such as atherosclerosis remain unknown. Accordingly, we investigated the inhibitory mechanisms of YOH in vascular smooth muscle cells (VSMCs) stimulated by platelet-derived growth factor (PDGF)-BB, a major mitogenic factor in vascular diseases. YOH (5-20 μM) suppressed PDGF-BB-stimulated a mouse VSMC line (MOVAS-1 cell) proliferation without inducing cytotoxicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!